Literature DB >> 30886497

Failure-to-Rescue Following Cytoreductive Surgery with or Without HIPEC is Determined by the Type of Complication-a Retrospective Study by INDEPSO.

Snita Sinukumar1, Sanket Mehta2, Dileep Damodaran3, Firoz Rajan4, Shabber Zaveri5, Mukurdipi Ray6, Ninad Katdare7, Kayomarz Sethna8, Mahesh D Patel9, Praveen Kammer2, Abraham Peedicayil10, Aditi Bhatt9.   

Abstract

To determine factors influencing failure-to-rescue in patients with complications following cytoreductive surgery and HIPEC. A retrospective analysis of patients enrolled in the Indian HIPEC registry was performed. Complications were graded according to the CTCAE classification version 4.3. The 30- and 90-day morbidity were both recorded. Three hundred seventy-eight patients undergoing CRS with/without HIPEC for peritoneal metastases from various primary sites, between January 2013 and December 2017 were included. The median PCI was 11 [range 0-39] and a CC-0/1 resection was achieved in 353 (93.5%). Grade 3-4 morbidity was seen 95 (25.1%) at 30 days and 122 (32.5%) at 90 days. The most common complications were pulmonary complications (6.8%), neutropenia (3.7%), systemic sepsis (3.4%), anastomotic leaks (1.5%), and spontaneous bowel perforations (1.3%). Twenty-five (6.6%) patients died within 90 days of surgery due to complications. The failure-to-rescue rate was 20.4%. Pulmonary complications (p = 0.03), systemic sepsis (p < 0.001), spontaneous bowel perforations (p < 0.001) and PCI > 20 (p = 0.002) increased the risk of failure-to-rescue. The independent predictors were spontaneous bowel perforation (p = 0.05) and systemic sepsis (p = 0.001) and PCI > 20 (p = 0.02). The primary tumor site did not have an impact on the FTR rate (p = 0.09) or on the grade 3-4 morbidity (p = 0.08). Nearly one-fifth of the patients who developed complications succumbed to them. Systemic sepsis, spontaneous bowel perforations, and pulmonary complications increased the risk of FTR and multidisciplinary teams should develop protocols to prevent, identify, and effectively treat such complications. All surgeons pursuing this specialty should perform a regular audit of their results, irrespective of their experience.

Entities:  

Keywords:  Cytoreductive surgery; Failure-to-rescue; Hyperthermic intraperitoneal chemotherapy; Peritoneal metastases

Year:  2019        PMID: 30886497      PMCID: PMC6397122          DOI: 10.1007/s13193-019-00877-x

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN: 0975-7651


  5 in total

1.  Quality Standards for Surgery of Colorectal Peritoneal Metastasis After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.

Authors:  Alfonso García-Fadrique; Rafael Estevan Estevan; Luis Sabater Ortí
Journal:  Ann Surg Oncol       Date:  2021-08-25       Impact factor: 5.344

2.  Total Parietal Peritonectomy Can Be Performed with Acceptable Morbidity for Patients with Advanced Ovarian Cancer After Neoadjuvant Chemotherapy: Results From a Prospective Multi-centric Study.

Authors:  Aditi Bhatt; Praveen Kammar; Snita Sinukumar; Loma Parikh; Nutan Jumle; Sakina Shaikh; Sanket Mehta
Journal:  Ann Surg Oncol       Date:  2020-08-03       Impact factor: 5.344

3.  Severe pulmonary complications after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy are common and contribute to decreased overall survival.

Authors:  Olivia Sand; Mikael Andersson; Erebouni Arakelian; Peter Cashin; Egidijus Semenas; Wilhelm Graf
Journal:  PLoS One       Date:  2021-12-28       Impact factor: 3.240

4.  Enhanced recovery after surgery (ERAS) in cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): a cross-sectional survey.

Authors:  Geetu Bhandoria; Sohan Lal Solanki; Mrugank Bhavsar; Kalpana Balakrishnan; Cherukuri Bapuji; Nitin Bhorkar; Prashant Bhandarkar; Sameer Bhosale; Jigeeshu V Divatia; Anik Ghosh; Vikas Mahajan; Abraham Peedicayil; Praveen Nath; Snita Sinukumar; Robin Thambudorai; Ramakrishnan Ayloor Seshadri; Aditi Bhatt
Journal:  Pleura Peritoneum       Date:  2021-06-21

5.  Platinum resistant recurrence and early recurrence in a multi-centre cohort of patients undergoing interval cytoreductive surgery for advanced epithelial ovarian cancer.

Authors:  Aditi Bhatt; Snita Sinukumar; Vahan Kepenekian; Praveen Kammar; Sanket Mehta; Sakina Shaikh; Witold Gertych; Naoual Bakrin; Olivier Glehen
Journal:  Front Oncol       Date:  2022-09-02       Impact factor: 5.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.